Lunai Bioworks Inc. 8-K Filing

FAQ

Key Financial Figures

• $0.0001 — h registered Common Shares, par value $0.0001 per share LNAI The Nasdaq Stock Marke
• $0.001 — 3 shares of its common stock, par value $0.001 per share (the "Shares"), at a purchase
• $1.00 — (the "Shares"), at a purchase price of $1.00 per share, and 1,044,444 three-year war
• $3,133,333 — rants") for aggregate gross proceeds of $3,133,333. The issuance and sale of the Shares a

Filing Documents

• e7070_8k.htm (8-K) — 36KB
• e7070_ex1-1.htm (EX-1.1) — 133KB
• 0001731122-25-001597.txt ( ) — 366KB
• lnai-20251125.xsd (EX-101.SCH) — 3KB
• lnai-20251125_lab.xml (EX-101.LAB) — 33KB
• lnai-20251125_pre.xml (EX-101.PRE) — 22KB
• e7070_8k_htm.xml (XML) — 4KB

Forward-Looking Statements

Forward-Looking Statements This report may contain forward-looking statements based on our beliefs and assumptions and on information currently available to us. Forward-looking statements can be identified by words such as "anticipates," "intends," "plans," "seeks," "believes," "estimates," "expects" and similar references to future periods, or by the inclusion of forecasts or projections. Examples of forward-looking statements include, but are not limited to, statements we make regarding the outlook for our future business and financial performance, estimated operational metrics, business strategy and plans and objectives of management for future operations, including, among other things, statements regarding the expected closing and terms of the Purchase Agreement.

Forward-looking statements

Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking are difficult to predict. As a result, actual results may differ materially from those contemplated by the forward-looking statements. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements and risk factors discussed from time to time in the Company's filings with the SEC, including, but not limited to, those described under the section entitled "Risk Factors" in our Annual Report on Form 10-Q filed with the SEC on November 14, 2025 and subsequent filings with the SEC, which can be found at the SEC's website at http://www.sec.gov. For the reasons described above, we caution you against relying on any forward-looking statements, which should also be read in conjunction with the other cautionary on which we make it. Factors or events that could cause actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. No recipient should, therefore, rely on these forward-looking statements as representing the views of the Company or its management as of any date subsequent to the date of this Current Report on Form 8-K. Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 1.1 Form of Securities Purchase Agreement 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2

Signatures

Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. David Weinstein By: /s/ David Weinstein David Weinstein Chief Executive Officer Date: November 25, 2025 3

View Full Filing

View this 8-K filing on SEC EDGAR